What are the key sales KPIs for the Specialty Pharmacy Distribution industry in 2027?

Direct Answer

The nine essential sales KPIs for specialty pharmacy distribution in 2027 are: Limited Distribution Drug (LDD) Network Slot Wins, Time to First Fill (Speed-to-Therapy), Prior Authorization (PA) Approval Rate, First Fill Rate, Patient Adherence (MPR/PDC), Refill Retention Rate, Patient Hub Services Attach Rate, Average Revenue Per Fill (ARPF), and DSO by Payer Channel.

Specialty pharmacy distribution sells access, speed, and adherence — not bulk Rx volume. The 9 KPIs above answer the three investor questions that matter: can you win the slot, can you fill it fast, and can you keep the patient on therapy long enough to make the gross margin work at 2-6%.

Why Specialty Pharmacy Distribution Works Differently

1. Margins Are Thin, Revenue Per Fill Is Massive. Specialty wholesale carries 2-6% gross margins versus 18-24% in generic distribution. But ARPF on a typical specialty fill runs $4,000-25,000, and a single gene therapy dispense can clear $1M-3.5M one-time.

That asymmetry means the revenue model is built around per-fill economics and patient retention, not unit volume. A 90-day refill miss on a $12,000/month biologic is roughly $36,000 of lost revenue from one patient — equivalent to thousands of generic scripts.

2. The LDD Network Is the Real Sales Channel. Roughly 60-70% of new specialty drugs launch into a Limited Distribution Drug network of 1-15 pharmacies per drug. Manufacturers pick the network.

Winning a slot is a competitive RFP process — win rate of 30-60% is typical — and a high-impact orphan drug slot can be worth $50M-500M in annual revenue. The sales motion is enterprise B2B (selling to manufacturers, payers, and health systems), not retail.

3. Speed-to-Therapy Is a Contracted Obligation. URAC accreditation standards require fills within 5 days of prescription receipt. Manufacturers contract on speed and adherence; payers contract on PA approval throughput.

Miss the SLA and you lose the slot. Time-to-fill is the single metric most likely to terminate a manufacturer contract, ahead of price or rebate terms.

4. The Patient Hub Is the Retention Engine. Patient hub services — benefits investigation, PA support, copay assistance, adherence outreach — are attached to 70-90% of specialty drugs, typically manufacturer-sponsored. The hub is what converts a first fill into a 12-fill annuity.

Pharmacies that own or integrate tightly with hubs (TrialCard/Mercalis, Sonexus, ConnectiveRx, Lash Group) compound retention; those that don't watch first-6-month discontinuation hit 25-40%.

The 9 KPIs, In Depth

1. Limited Distribution Drug (LDD) Network Slot Wins — Tracked as RFP win rate and total active slots. Best-in-class enterprise specialty pharmacies (CVS Specialty, Accredo, Optum Specialty) maintain 50-60% RFP win rates on competitive networks; mid-tier independents like Soleo Health or Senderra run 30-45%. Average annual revenue per slot ranges $50M-500M for orphan/oncology drugs; $5M-50M for chronic specialty. The slot count is the single best leading indicator of forward revenue — every slot lost compounds over 3-5 years of patient backbook.

1. Time to First Fill (Speed-to-Therapy) — URAC standard is under 5 days from prescription receipt to dispense. Best-in-class operators average 2-3 days; CVS Specialty publishes a 2.5-day median, Accredo reports under 3 days, and high-touch independents like Onco360 hit 1.5-2 days on oncology where speed is clinically critical. Anything above 7 days triggers manufacturer SLA penalties and patient abandonment. Speed-to-therapy is the metric LDD network owners cite first in renewal reviews.

1. Prior Authorization (PA) Approval Rate — First-submission PA approval runs 80-90% across the top operators; with appeals, the recovered rate reaches 95-99%. Optum Specialty and Accredo both publish first-pass rates above 88% thanks to integrated CoverMyMeds and proprietary payer rules engines. Independents using TherigySTM or manual workflows often sit at 72-78% first-pass. Each missed PA costs roughly 4-7 days of fill delay, which compounds into churn.

1. First Fill Rate — Percentage of new prescriptions that result in a dispensed first fill within 14 days of receipt. Target is 85-92%. CVS Specialty hits 90%+ on chronic categories; AnovoRx and Soleo Health report 87-89% on rare disease books. Drop below 80% and the LDD scorecard from the manufacturer will flag — typical contractual floor is 82%. First fill rate is the highest-velocity churn signal in the funnel.

1. Patient Adherence (MPR / PDC) — Medication Possession Ratio and Proportion of Days Covered, both targeting above 80% for high-complexity therapies. URAC and manufacturer pay-for-performance contracts increasingly tie reimbursement to adherence outcomes — Accredo and Optum Specialty report MPR of 82-86% on biologics versus 72-76% industry baseline for retail-dispensed equivalents. Every 5-point MPR drop typically translates to 8-12% revenue leakage from refill loss.

1. Refill Retention Rate — Percentage of patients still active at 12 months from first fill. Chronic specialty (rheumatology, MS, HIV) runs 90-94% retention at top-tier pharmacies. Oncology runs lower (60-75%) due to clinical course endpoints. CVS Specialty and Accredo both publish 92%+ on biologic categories; emerging cell and gene therapy retention is lower simply because the modality is single-dose. First-6-month discontinuation industry-wide is 25-40% — operators below that are credibly differentiated.

1. Patient Hub Services Attach Rate — Percentage of dispenses connected to a manufacturer-sponsored hub (benefits investigation, copay support, adherence). Industry attach is 70-90%, with the top three — CVS Specialty, Accredo, Optum Specialty — at 85-92% because their captive hub or hub partner is preferred. Sonexus (Cardinal Health), TrialCard/Mercalis, Lash Group (Cencora), ConnectiveRx, and Eversana run the bulk of manufacturer hub volume. Hub attach is the strongest correlate to 12-month retention.

1. Average Revenue Per Fill (ARPF) — $4,000-25,000 typical specialty fill; gene therapy fills $1M-3.5M one-time. CVS Specialty book ARPF runs $8,500-9,500 blended; Accredo around $9,000-10,500; Onco360 oncology-only book runs $14,000-18,000. ARPF mix shift is the most leveraged sales lever — moving 5 points of mix toward orphan/oncology can lift gross profit dollars 20-30% even at flat fill counts. Wholesalers (Cencora ~$262B revenue, McKesson ~$280B, Cardinal Health ~$205B) blend specialty into wholesale ARPF that runs lower per unit but higher per case.

1. DSO by Payer Channel — Days sales outstanding splits sharply by channel: 18-30 days for commercial and Medicare Part D, 5-15 days for self-pay/copay assistance, and 45-75 days for Medicaid in non-MCO states. With 2-6% gross margin, every 10 days of DSO erodes annualized margin by roughly 30-50 bps. Accredo and Optum Specialty publish blended DSO under 25 days; independents and 340B-heavy operators often sit at 38-50 days. DSO is the CFO's primary specialty metric and increasingly a board-level KPI in 2027 transparency reporting.

Real Operators

CVS Specialty (CVS Health) — Largest US specialty pharmacy by revenue, vertically integrated with Caremark PBM and Aetna payer. Publishes 2.5-day median time-to-fill and 90%+ first fill rates on chronic categories.

Accredo (Cigna / Evernorth) — Roughly $45B+ specialty revenue, second largest by volume. Operates the Therigy adherence platform and integrates with Express Scripts PBM. PA first-pass rates above 88%.

Optum Specialty Pharmacy (UnitedHealth Group) — Third-largest specialty, absorbed Diplomat (2020) and BriovaRx. Owns the BriovaRx Infusion Services and Genoa Healthcare community footprint. Integrated with OptumRx PBM.

Onco360 (PharMerica) — Oncology-focused specialty pharmacy, ARPF in the $14,000-18,000 range; 1.5-2 day time-to-fill on oral oncolytics. Recognized for clinical pharmacist model and integration with US Oncology Network.

Soleo Health — Mid-tier independent specialty pharmacy, focused on rare disease and home infusion. Known for 87-89% first fill rate on ultra-orphan therapies and high-touch nurse model.

Senderra Specialty Pharmacy — Independent specialty operator, dermatology and rheumatology focus, 30-45% LDD RFP win rate competing against the Big 3.

AnovoRx — Independent rare-disease specialty pharmacy, strong in cell and gene therapy logistics. Frequently named in LDD networks for ultra-orphan launches.

Cencora (formerly AmerisourceBergen, ~$262B revenue) — Largest specialty wholesaler; owns ASD Healthcare, Besse Medical, TheraCom specialty distribution, plus the Lash Group patient services hub.

Cardinal Health (~$205B revenue) — Operates ICS (Innovative Choice Specialty), Sonexus patient hub, and Onmark oncology GPO. Specialty distribution arm tied tightly to community oncology.

McKesson (~$280B revenue) — McKesson Specialty Health includes CoverMyMeds (PA platform, the dominant prior-auth network), the US Oncology Network, and specialty distribution to retail and health systems.

Curant Health — Independent specialty pharmacy with adherence-focused model; published MPR results above 84% on chronic categories.

Avita Pharmacy — 340B-focused specialty operator serving HIV, hepatitis, and behavioral health covered entities. Significant footprint in 340B contract pharmacy network.

Failure Modes

1. Losing LDD Slots You Already Have — Renewal cycles are 2-3 years and the manufacturer scorecard runs on time-to-fill, first-fill rate, adherence, and patient satisfaction. Operators that under-invest in hub integration or PA throughput see slot count erode 5-10% per renewal cycle. Cumulative effect over 3 cycles is roughly half your specialty book gone — and you don't get the slot back.

1. Chasing Volume At Negative Net Margin — 340B and Medicaid fills can carry effective gross margins under 2% after rebate pass-through and DSO drag. Operators that pile on these fills to grow top-line without channel-mix discipline routinely report flat or negative gross profit despite revenue growth. The 2026-27 transparency wave has accelerated this — PBM 100% rebate pass-through compresses the channel further.

1. Hub Disconnect Driving Discontinuation — First-6-month discontinuation runs 25-40% industry-wide and concentrates in patients who never engaged with the manufacturer hub. Operators that treat hub as a referral-out rather than a workflow integration lose 8-15 points of 12-month retention. Once a patient discontinues, getting them back is roughly 4x the cost of original onboarding.

1. Manual PA Workflows In A CoverMyMeds World — PA first-pass rates of 72-78% on manual workflows versus 88-92% on integrated CoverMyMeds + payer rules engines is now a 10-15 point gap. Every missed first-pass PA costs 4-7 days of fill delay and ~10% of those patients abandon therapy. Operators still running fax-and-phone PA in 2027 are structurally uncompetitive on the metrics manufacturers grade.

Reporting Cadence

Daily

• Fills dispensed by category (chronic, oncology, rare, ultra-orphan)
• PA queue depth and aging
• Time-to-fill running median (target under 5 days, world-class under 3)
• Inventory exceptions on cold chain and limited-supply SKUs
• Patient call-center service level (target 80/30 on hub-supported lines)

Weekly

• LDD pipeline by stage (RFP-active, awarded, onboarding)
• First fill rate by category and prescriber cohort
• Patient hub attach rate
• New patient starts versus forecast
• Cold-chain shipment exceptions

Monthly

• ARPF blended and by category mix
• Adherence (MPR/PDC) by cohort and drug
• DSO by payer channel
• Discontinuation rate at 30/60/90/180 days
• Manufacturer scorecard scores received

Quarterly

• LDD slot scorecard from manufacturers (the renewal currency)
• 340B contract pharmacy participation and revenue
• Refill retention at 12 months by cohort
• Rebate pass-through and net economics post-2027 transparency rules
• URAC accreditation gap audit

30/60/90 Day Plan

Days 1-30 — Instrument every fill end-to-end: prescription receipt timestamp, PA submitted timestamp, PA approved timestamp, hub enrolled timestamp, dispensed timestamp. Reconcile against the manufacturer scorecards already in flight for every active LDD. Baseline time-to-fill, first-fill rate, PA first-pass, and hub attach at the SKU level.

Identify the bottom-quartile drugs by speed-to-therapy and stand up daily standups for those teams.

Days 31-60 — Connect CoverMyMeds (or equivalent) to every PA workflow that is still manual; target a 10-point lift in PA first-pass rate within 60 days. Deploy hub-attach dashboards tied to manufacturer hub APIs (Sonexus, TrialCard/Mercalis, ConnectiveRx, Lash Group) so attach rate is visible per fill, not aggregated monthly.

Begin the LDD pipeline review for any slot inside its 12-month renewal window — manufacturer scorecards stop being negotiable inside 6 months.

Days 61-90 — Re-forecast ARPF mix targeting 3-5 point shift toward oncology/rare/ultra-orphan if the slot portfolio allows; rebalance sales effort and inventory accordingly. Stand up the DSO-by-channel CFO dashboard with weekly refresh; identify the two payer channels driving the most DSO drag and route them to a dedicated AR team.

Submit RFPs for any open or expiring LDD slots with full speed and adherence telemetry — the new bid template should lead with median time-to-fill, PA first-pass, and 12-month refill retention.

FAQ

What's the single most important specialty pharmacy KPI in 2027? LDD slot count and slot retention. Every other KPI feeds slot retention, and slot count is the single best forward-revenue indicator. An operator that holds slots through renewal cycles compounds; one that loses them watches revenue erode 5-10% per renewal regardless of dispensing performance.

How does PBM transparency change the metrics in 2027? The 100% rebate pass-through wave compresses gross margins by roughly 100-200 bps and makes DSO and channel mix far more important. Operators that previously made the P&L work on rebate retention now have to make it work on adherence, hub attach, and ARPF mix toward higher-value categories.

The KPI dashboard tilts harder toward retention metrics and away from rebate metrics.

Are gene and cell therapy fills measured the same way? No. Gene therapy is typically a single $1M-3.5M one-time dispense; adherence and refill retention don't apply. The KPIs that matter are time-to-treatment (often 6-12 weeks including manufacturing), patient identification accuracy, and outcomes-based contract performance.

Operators serving CGT (AnovoRx, Onco360, parts of CVS Specialty) report a parallel KPI set focused on patient journey rather than refill cycles.

What separates the Big 3 from independent specialty pharmacies? Scale, captive PBM/hub integration, and LDD slot count. CVS Specialty, Accredo, and Optum Specialty hold a disproportionate share of competitive LDD slots because of Caremark, Express Scripts, and OptumRx PBM gravity.

Independents win on clinical depth, speed, and willingness to serve smaller patient populations — Onco360 in oncology, Soleo Health in rare disease, Senderra in dermatology/rheumatology.

How do 340B contract pharmacies affect specialty KPIs? 340B contract pharmacy locations (about 25,000+ in 2026) carry attractive sticker margins but increasingly compressed effective economics after manufacturer carve-outs and HRSA disputes. Specialty operators with 340B exposure (Avita is the cleanest example) need separate KPI scorecards — channel margin after carve-outs, contract-entity retention, and HRSA audit readiness matter more than blended numbers.

Which technology stack does best-in-class run on? Dispensing on CareTend (CHS), CPR+ (CarepathRx), or McKesson EnterpriseRx. PA on CoverMyMeds. Adherence on TherigySTM or proprietary stacks.

Hub integration via Sonexus, TrialCard/Mercalis, ConnectiveRx, or Lash Group APIs. Adherence devices from AdhereTech, Pillsy, or Medisafe layered onto the highest-cost SKUs.

Sources

• IQVIA Institute, U.S. Specialty Pharmacy Outlook 2025-2027
• Drug Channels Institute, Specialty Pharmacy Market Report 2026
• URAC, Specialty Pharmacy Accreditation Standards v5.0 (2026)
• Pharmacy Times, 2026 Top Specialty Pharmacies by Revenue
• CMS, Medicare Part D Specialty Tier Data 2025-2026
• Adam J. Fein, PhD, Drug Channels Annual Outlook 2027
• ASHP, Specialty Pharmacy Practice Guidelines 2026
• NCPA Digest 2026, Independent Specialty Pharmacy Trends
• Cencora 10-K Annual Report 2025 (specialty distribution segment)
• Cardinal Health 10-K Annual Report 2025 (specialty solutions segment)
• McKesson 10-K Annual Report 2025 (US Pharmaceutical segment)
• Pew Charitable Trusts, 340B Contract Pharmacy Trends 2026
• HRSA OPA, 340B Program Statistics 2026
• Frier Levitt Specialty Pharmacy Law Report 2026
• CoverMyMeds 2026 Medication Access Report